SV investment has resulted in the approval of 24 novel therapeutics
SV News
13 May 2020Portfolio NewsAVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis- 12 May 2020Portfolio NewsCatabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
12 May 2020Portfolio NewsBicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics- 6 May 2020Portfolio NewsAVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
- 5 May 2020Portfolio NewsBicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab
- 4 May 2020Portfolio NewsAVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally
1 May 2020SV NewsHow the UK life sciences industry is rising to the challenge of Covid-19 by Kate Bingham- 28 April 2020Portfolio NewsKarus Therapeutics Announces New Data from Phase I Cancer Trial at AACR
27 April 2020Portfolio NewsXilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer to lead XTX201 (tumor-selective IL-2) and XTX101 (tumor-Selective aCTLA-4) into the clinic while xilio continues to advance its tumor-selective cytokine pipeline- 27 April 2020Portfolio NewsSutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
- 13 April 2020Portfolio NewsSutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
- 7 April 2020Portfolio NewsBicycle Therapeutics Announces Pipeline Progress Update
